BCAX Q3 2023 Earnings Report — Bicara Therapeutics Inc. Common Stock Revenue & Financial Results | Market Cap Arena

Bicara Therapeutics Inc. Common StockBCAX

Q3 2023 Earnings

Reported September 30, 2023

Quarter Comparison

Revenue

Operating Income

EPS (Diluted)

Free Cash Flow

Metric	Q3 2023	Q2 2023	Q3 2022	QoQ Change	YoY Change
Revenue	$0	$0	—	—	—
Op. Income	-$10M	-$8M	—	-14.3%	—
EPS (Diluted)	$-0.42	$-0.15	—	-180.0%	—
Free Cash Flow	-$11M	-$14M	—	21.0%	—

Income Statement

Item	Amount
REVENUE	$0
Cost of Revenue	$0
GROSS PROFIT	$0
R&D Expenses	$7M
Selling & Marketing	$0
General & Administrative	$3M
SG&A Expenses	$3M
Other Expenses	$0
Operating Expenses	$10M
Cost & Expenses	$10M
OPERATING INCOME	-$10M
Interest Income	$13.0K
Interest Expense	$0
Other Income/Expenses	-$13M
INCOME BEFORE TAX	-$23M
Income Tax Expense	$0
Net Income from Continuing Ops	-$23M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	-$23M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	-$23M
D&A	$2.0K
EBIT	-$10M
EBITDA	-$10M
EPS	-$0
EPS Diluted	-$0

Cash Flow Statement

Item	Amount
Net Income	-$23M
Depreciation & Amortization	$2.0K
Stock-Based Compensation	$519.0K
Deferred Income Tax	$0
Other Non-Cash Items	$13M
Change in Working Capital	-$2M
OPERATING CASH FLOW	-$11M
Capital Expenditure	-$150.0K
Acquisitions (Net)	$0
Purchases of Investments	$0
Sales/Maturities of Investments	$0
Other Investing Activities	$0
NET CASH FROM INVESTING	-$150.0K
Net Debt Issuance	$0
Common Stock Repurchased	$0
Common Dividends Paid	$0
Other Financing Activities	$84.0K
NET CASH FROM FINANCING	$40M
FREE CASH FLOW	-$11M
Net Change in Cash	$29M